Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy.

Ye-Ping MaYue YangShi-Min JiangLin LiuZheng ZhangYi-Ning WangGu-Ming ZouWen-Ge Li

Published in: Journal of the renin-angiotensin-aldosterone system : JRAAS (2021)

Our results directly observed that renal expression levels of AT1R increase during the early stages of DN, ARB reducing AT1R while increasing MAS receptor. Therefore, ARB should be used as soon as possible in patients with DN.

Keyphrases

angiotensin ii
angiotensin converting enzyme
diabetic nephropathy
vascular smooth muscle cells
poor prognosis
binding protein